/PRNewswire/ Coave Therapeutics ( Coave ), a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare Ocular and CNS.
Kurma Partners announced the first closing of its Growth Opportunities fund at €160 million. Meeting the demand of the growing maturity of the European biotech and healthtech ecosystem, this new fund